

# TABLE OF CONTENTS

## FROM THE EDITOR

### **All sulfa drugs are not created equal 136**

Misinformation about “sulfa allergy” can result in unnecessary avoidance of useful medications and the prescription of less effective alternatives.

Brian F. Mandell, MD, PhD

## THE CLINICAL PICTURE

### **Sarcoidosis with diffuse purplish erythematous plaques on the hands 145**

A 70-year-old woman presented in winter with a 1-month history of asymptomatic redness of the hands.

Akihiro Orita, MD; Mitsuhiro Ota, MD, PhD

## 1-MINUTE CONSULT

### **Can my patient with a ‘sulfa allergy’ receive celecoxib or other nonantimicrobial sulfonamides? 147**

There is no cross-reactivity between antimicrobial and nonantimicrobial sulfonamides, and patients with a history of immunoglobulin E–mediated reaction to a sulfonamide antibiotic can receive nonantimicrobial sulfonamides.

Nicholas B. Cline, MD; Amudha Pazhanisamy, DO; David M. Lang, MD

## GUIDELINES TO PRACTICE

CME MOC

### **Hyperglycemic crises in adults: A look at the 2024 consensus report 152**

A new report introduces revised criteria for the diagnosis of diabetic ketoacidosis and hyperglycemic hyperosmolar state, as well as new recommendations for assessment, management, and prevention of these disorders.

Paloma Rodriguez Alvarez, MD; Vicente T. San Martin, MD; Oscar L. Morey-Vargas, MD

## REVIEW

### **Cardiovascular disease in people living with HIV: Risk assessment and management 159**

Because people living with HIV develop coronary artery disease much earlier than the general population, careful attention must be given to assessment and management of their cardiovascular risk.

Elizabeth Ghandakly, MD, JD; Rohit Moudgil, MD, PhD; Katherine Holman, MD

## EDITORIAL

### **Heart to heart: Progress in cardiovascular disease prevention for people living with HIV 168**

The already higher cardiovascular risk in people living with HIV is exacerbated by social determinants of health such as socioeconomic status, access to healthcare, and systemic discrimination. Interventions that address this risk must be based in medical science and equity.

James Hekman, MD; Henry H. Ng, MD, MPH

CONTINUED ON PAGE 134

CONTINUED FROM PAGE 132


## REVIEW

**Psychedelic-assisted therapy: An overview for the internist 171**

The authors review the potential effects, risks, and therapeutic applications of the psychedelic drugs MDMA (Ecstasy) and psilocybin, with a focus on MDMA-assisted therapy for posttraumatic stress disorder and psilocybin-assisted therapy for depression.

Brian S. Barnett, MD; Erin E. Mauney, MD; Franklin King IV, MD

## REVIEW


**Coronary artery bypass grafting: Practice trends and projections 181**

Future directions include expanding the use of multiarterial grafting, offering patients less-invasive approaches, and enhancing operative recovery.

Richard Ramsingh, MD; Faisal G. Bakaeen, MD

## LETTERS TO THE EDITOR

**Effective but inaccessible antiobesity medications 141**

Sima Saberi, MD; Sabiha M. Hussain, MD; Mohammad Kazem Fallahzadeh, MD, MAS; Hector Madariaga, MD; Pooja Budhiraja, MBBS; Kenneth J. Woodside, MD

**Classic diabetic ketoacidosis and the euglycemic variant 142**

Param Darpan Sheth, MBBS

**In Reply: Classic diabetic ketoacidosis and the euglycemic variant 142**

Adi E. Mehta, MD; Robert Zimmerman, MD

**Insomnia in older adults 143**

Anup Katyal, MD

**In Reply: Insomnia in older adults 144**

Margaret M. Chaplain, MD; Roberto León-Barriera, MD; Vania Modesto-Lowe, MD, MPH

## DEPARTMENTS

**CME Calendar 138**
**CME/MOC Instructions 192**
**CME/MOC CREDIT**

**Test your knowledge  
of clinical topics and earn  
AMA PRA Category 1 Credit™  
and ABIM MOC points**

[www.ccjm.org/content/latest-articles-cmemoc](http://www.ccjm.org/content/latest-articles-cmemoc)

CLEVELAND  
CLINIC  
JOURNAL OF  
MEDICINE